CN1946398B - 噻二唑二酮作为gsk-3抑制剂 - Google Patents

噻二唑二酮作为gsk-3抑制剂 Download PDF

Info

Publication number
CN1946398B
CN1946398B CN2005800121414A CN200580012141A CN1946398B CN 1946398 B CN1946398 B CN 1946398B CN 2005800121414 A CN2005800121414 A CN 2005800121414A CN 200580012141 A CN200580012141 A CN 200580012141A CN 1946398 B CN1946398 B CN 1946398B
Authority
CN
China
Prior art keywords
disease
chemical compound
medicine
formula
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800121414A
Other languages
English (en)
Chinese (zh)
Other versions
CN1946398A (zh
Inventor
安娜·马丁纳茨吉尔
伊莎贝尔·多龙索罗迪亚斯
默西迪斯·阿郎索切斯孔
赫马·帕尼索德尔普列戈
安娜·富埃尔特韦尔塔
玛丽亚何塞·佩雷斯普埃尔托
米格尔·麦迪纳帕迪拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asd Treatment Partnership Ltd
Original Assignee
Neuropharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1946398(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuropharma SA filed Critical Neuropharma SA
Publication of CN1946398A publication Critical patent/CN1946398A/zh
Application granted granted Critical
Publication of CN1946398B publication Critical patent/CN1946398B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
CN2005800121414A 2004-04-05 2005-04-04 噻二唑二酮作为gsk-3抑制剂 Expired - Lifetime CN1946398B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04075997.9 2004-04-05
EP04075997A EP1586318A1 (en) 2004-04-05 2004-04-05 Thiadiazolidinones as GSK-3 inhibitors
PCT/EP2005/003613 WO2005097117A1 (en) 2004-04-05 2005-04-04 Thiadiazolidinones as gsk-3 inhibitors

Publications (2)

Publication Number Publication Date
CN1946398A CN1946398A (zh) 2007-04-11
CN1946398B true CN1946398B (zh) 2011-03-30

Family

ID=34928129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800121414A Expired - Lifetime CN1946398B (zh) 2004-04-05 2005-04-04 噻二唑二酮作为gsk-3抑制剂

Country Status (29)

Country Link
US (2) US7531561B2 (enExample)
EP (2) EP1586318A1 (enExample)
JP (1) JP4995076B2 (enExample)
KR (1) KR101151647B1 (enExample)
CN (1) CN1946398B (enExample)
AR (2) AR048820A1 (enExample)
AT (1) ATE446090T1 (enExample)
AU (1) AU2005230392B2 (enExample)
BR (1) BRPI0508788A (enExample)
CA (1) CA2559740C (enExample)
CY (1) CY1109724T1 (enExample)
DE (1) DE602005017215D1 (enExample)
DK (1) DK1586319T3 (enExample)
EC (1) ECSP066858A (enExample)
ES (1) ES2335505T3 (enExample)
HR (1) HRP20100032T1 (enExample)
IL (1) IL178125A (enExample)
MA (1) MA28515B1 (enExample)
MX (1) MXPA06011194A (enExample)
NO (1) NO332751B1 (enExample)
NZ (1) NZ549904A (enExample)
PL (1) PL1586319T3 (enExample)
PT (1) PT1586319E (enExample)
RS (1) RS51340B (enExample)
RU (1) RU2379300C2 (enExample)
SI (1) SI1586319T1 (enExample)
TW (1) TWI352084B (enExample)
WO (1) WO2005097117A1 (enExample)
ZA (1) ZA200608221B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408747C (en) 2000-05-11 2011-04-05 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
ES2258406B1 (es) * 2005-02-10 2007-12-01 Neuropharma, S.A. Uso de compuestos heterociclicos como agentes neurogenicos.
EP1749523A1 (en) * 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
AU2007275686B2 (en) * 2006-07-18 2013-10-31 University Of Rochester Thiadiazolidinone derivatives
WO2008012031A2 (en) * 2006-07-25 2008-01-31 Universität Bern Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
MX2009004140A (es) 2006-10-21 2009-07-10 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
KR100829468B1 (ko) * 2007-01-17 2008-05-16 한국화학연구원 신규한 1,2,4-티아다이아졸리딘-3,5-다이온 화합물 및 이의제조방법
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011151359A1 (en) * 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
MX336726B (es) 2010-09-27 2016-01-27 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
WO2012065065A1 (en) * 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8865750B2 (en) 2011-04-28 2014-10-21 The Regents Of The University Of Michigan Small molecule inhibitors of RGS proteins
EP2527323A1 (en) 2011-05-24 2012-11-28 Noscira, S.A. Urea carbonyl disulfide derivatives and their therapeutic uses
WO2012170657A1 (en) * 2011-06-07 2012-12-13 Georgetown University Targeting gsk-3beta for the treatment of parkinson's disease
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2838888B1 (en) 2012-02-24 2017-04-12 ASD Therapeutics Partners LLC Thiadiazolidinediones as gsk-3 inhibitors
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
CN103992312A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
CN103992313A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途
WO2015075051A1 (en) 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP3154544B1 (en) * 2014-06-12 2023-08-02 Cedars-Sinai Medical Center Compositions and methods for treating cancers
CN107151235B (zh) * 2016-03-04 2019-12-13 上海市计划生育科学研究所 噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
EP3426247A1 (en) * 2016-03-10 2019-01-16 Alma Mater Studiorum -Universita' di Bologna Treatment of cdkl5 disorders with gsk3 inhibitor tideglusib
GB201617820D0 (en) * 2016-10-21 2016-12-07 King S College London Dental treatment
WO2018226721A1 (en) * 2017-06-06 2018-12-13 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus using a gsk-3 inhibitor
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN113827592B (zh) * 2020-06-24 2024-06-18 中国科学院上海药物研究所 一种噻二唑烷二酮基化合物在治疗致病性感染中的应用
US12150936B2 (en) * 2021-02-11 2024-11-26 Venca Research, Inc. Compositions and methods for treating arrhythmogenic cardiomyopathy
US20240173304A1 (en) 2021-02-24 2024-05-30 Teva Pharmaceuticals International Gmbh Solid state forms of tideglusib and process for preparation thereof
WO2022243973A1 (en) 2021-05-21 2022-11-24 Amo Pharma Ltd. Method of treating rna repeat mediated diseases with rna repeat binding compound
EP4094760A1 (en) 2021-05-24 2022-11-30 Consejo Superior De Investigaciones Científicas Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
CN116675653B (zh) * 2022-07-22 2024-10-01 中国药科大学 氨基烷基取代的1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
CN117986202B (zh) * 2024-04-03 2024-06-14 中国药科大学 具有ptpn2抑制活性的1，2，4-噻二唑烷-3，5-二酮化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
CA2408747C (en) * 2000-05-11 2011-04-05 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors

Also Published As

Publication number Publication date
AU2005230392B2 (en) 2011-03-24
AR104417A2 (es) 2017-07-19
CA2559740C (en) 2014-06-10
MA28515B1 (fr) 2007-04-03
NO332751B1 (no) 2013-01-07
CN1946398A (zh) 2007-04-11
EP1586319B1 (en) 2009-10-21
HRP20100032T1 (hr) 2010-03-31
US8158661B2 (en) 2012-04-17
RU2379300C2 (ru) 2010-01-20
NZ549904A (en) 2010-08-27
NO20064456L (no) 2006-10-02
IL178125A0 (en) 2006-12-31
ZA200608221B (en) 2008-08-27
RS51340B (sr) 2011-02-28
WO2005097117A1 (en) 2005-10-20
ECSP066858A (es) 2007-01-26
PL1586319T3 (pl) 2010-06-30
KR20060131976A (ko) 2006-12-20
CA2559740A1 (en) 2005-10-20
JP4995076B2 (ja) 2012-08-08
PT1586319E (pt) 2010-01-21
US20050222220A1 (en) 2005-10-06
US7531561B2 (en) 2009-05-12
MXPA06011194A (es) 2007-03-21
HK1100426A1 (en) 2007-09-21
AR048820A1 (es) 2006-05-31
SI1586319T1 (sl) 2010-02-26
IL178125A (en) 2012-01-31
JP2007531782A (ja) 2007-11-08
EP1586319A1 (en) 2005-10-19
ATE446090T1 (de) 2009-11-15
KR101151647B1 (ko) 2012-06-08
ES2335505T3 (es) 2010-03-29
CY1109724T1 (el) 2014-08-13
TWI352084B (en) 2011-11-11
EP1586318A1 (en) 2005-10-19
DK1586319T3 (da) 2010-02-08
TW200538119A (en) 2005-12-01
AU2005230392A1 (en) 2005-10-20
US20090233971A1 (en) 2009-09-17
BRPI0508788A (pt) 2007-09-04
DE602005017215D1 (de) 2009-12-03
RU2006139030A (ru) 2008-05-20

Similar Documents

Publication Publication Date Title
CN1946398B (zh) 噻二唑二酮作为gsk-3抑制剂
KR101471999B1 (ko) Ｇｓｋ-3 저해제
ES2731525T3 (es) Aminas terciarias para su uso en el tratamiento de trastornos cardíacos
HK1100426B (en) Thiadiazolidinones as gsk-3 inhibitors
US7678789B2 (en) [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-S-transferase and NADPH quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular
HK1124761B (en) Gsk-3 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1100426

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Madrid

Patentee after: NOSCIRA, S.A.

Address before: Madrid

Patentee before: NEUROPHARMA, S.A.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1100426

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210108

Address after: New jersey, USA

Patentee after: ASD treatment Partnership Ltd.

Address before: Xi Banyamadeli

Patentee before: NOSCIRA, S.A.

CX01 Expiry of patent term

Granted publication date: 20110330

CX01 Expiry of patent term